CAJ | 학술논문

目的:研究替米沙坦对心力衰竭(CHF)患者血清中肿瘤坏死因子-α(TNF-a)、白细胞介素-6(IL-6)水平的影响.方法:采用放射免疫方法检测 TNF-α、IL-6,对比53例接受替米沙坦治疗的 CHF 患者同53例常规治疗 CHF 患者治疗前后血清中 TNF-α、IL-6的水平.结果:经4周治疗后,替米沙坦治疗组心功能明显改善,血浆 TNF-α和 IL-6的水平显著降低(P<0.01),总临床有效率好于常规治疗组,但比较差异无统计学意义(P>0.05).结论:替米沙坦比常规治疗更能改善心功能,降低 TNF-α、IL-6的水平,可使心脏损伤进程延缓,对 CHF 患者的心功能有保护和改善作用.
목적:연구체미사탄대심력쇠갈(CHF)환자혈청중종류배사인자-α(TNF-a)、백세포개소-6(IL-6)수평적영향.방법:채용방사면역방법검측 TNF-α、IL-6,대비53례접수체미사탄치료적 CHF 환자동53례상규치료 CHF 환자치료전후혈청중 TNF-α、IL-6적수평.결과:경4주치료후,체미사탄치료조심공능명현개선,혈장 TNF-α화 IL-6적수평현저강저(P<0.01),총림상유효솔호우상규치료조,단비교차이무통계학의의(P>0.05).결론:체미사탄비상규치료경능개선심공능,강저 TNF-α、IL-6적수평,가사심장손상진정연완,대 CHF 환자적심공능유보호화개선작용.
Objective:To investigate the effects of telmisartan on cardiac function and serum levels of tumor necrosis factor-α(TNF-α), interleukin -6(IL-6)in patients with congestive heart failure(CHF).Method:The levels of serum TNF-α,IL-6 were determined by radioimmunoassay in 106 CHF cases(53 of whom were treated by telmisartan and other 53 were treated by conventional treatment).Result:After 4-week treatment,the NYHA classification and the plasma levels of TNF-α and IL-6 decreased significantly in the telmisartan group(P<0.01),although the clinical efficacy in the candesartan group showed better improvement than the control group,but not reached statistical significant(P>0.05). Conclusion:The efficacy of telmisartan is effective and safe for patients with CHF,and significant reduction of the plasma TNF-α and IL-6 Levels.